Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | GRM8 | O00222 | 1/20 | 0.51 |
| ▸ | GRM6 | O15303 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.51 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL2247133 | 0.87 | KIF11 (0.43) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| Glutamic Acid SCHEMBL1674904 | 0.86 | GRM8 (0.64) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| Biphenyl SCHEMBL7780462 | 0.83 | SLC1A3 (0.69) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| D-Glutamate SCHEMBL3417211 | 0.81 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| Glutamic Acid SCHEMBL3417216 | 0.81 | SLC1A3 (0.67) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| D-Glutamate SCHEMBL27568760 | 0.78 | MMP9 (0.45) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| Glutamic Acid SCHEMBL7900440 | 0.77 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| Biphenyl SCHEMBL27728793 | 0.76 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| Phthalic Anhydride SCHEMBL28197593 | 0.76 | GRM8 (0.58) | SLC1A3SLC1A2SLC1A1GRM8GRM6 | |
| D-Glutamate SCHEMBL6486892 | 0.76 | GRM8 (0.90) | SLC1A3SLC1A2SLC1A1GRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | SLC1A3 61/4885SLC1A2 68/4885SLC1A1 60/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | SLC1A3 61/4885SLC1A2 68/4885SLC1A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.